Lebanon Pharmaceuticals & Healthcare Report Q2 2015
Headline Expenditure Projections
- Pharmaceuticals : LBP2,394.38bn (USD1.59bn) in 2014 to LBP2,594.09bn (USD1.60bn) in 2015; +8.3% in local currency and +0.7% in US dollar terms.
- Healthcare: LBP5,581.06bn (USD3.70bn) in 2014 to LBP6,071.98bn (USD3.74bn) in 2015; +8.8% in local currency and +1.1% US dollar terms.
For Q2 2015, Lebanon's Pharmaceutical Risk/Reward Index score is calculated at 52.0 out of 100, lower than last quarter's score of 54.7, ranking the country sixth in the Middle East and Africa matrix, one place above last quarter's position.
Key Trends & Developments
January 2015: As part of an anti-corruption campaign in the health sector, Lebanon's Health Minister Wael Abu Faour issued warnings to three pharmacists as well as requesting disciplinary measures against a medical doctor, the Daily Star reports. Also, in a separated statement later that day, Abu Faour revealed the Health Ministry's decision to terminate its contract with the Hayat Hospital in Beirut's southern suburbs over the hospital's 'bad dealings with patients', no further details were given at the time.
The Lebanese Health Minister has stopped a work procedure under which physician and hospital charges were separated. The Minister requested the Order of Physicians to ensure the proper implementation of the unified medical prescription. The unified prescription allows for the purchase of generic medication, which are as effective as brand...
The Lebanon Pharmaceuticals & Healthcare Report features Business Monitor International (BMI)'s forecasts for drugs and healthcare expenditure and imports and exports, focusing on the growth outlook for the prescription, OTC, patented drugs and generics market segments.
BMI's Lebanon Pharmaceuticals & Healthcare Report provides industry professionals, strategists, company executives, investors, analysts and sales/marketing heads with independent forecasts and competitive intelligence on the Lebanon pharmaceutical and healthcare industry.
- Benchmark BMI's pharmaceutical and healthcare market forecasts for Lebanon, to test other views - a key input for successful budgeting and strategic business planning in the Lebanese pharmaceutical and healthcare market.
- Target business opportunities and risks in the Lebanese pharmaceutical and healthcare sector through our reviews of latest industry trends, regulatory changes and major deals, projects and investments in Lebanon.
- Assess the activities, strategy and market position of your competitors using our company profiles (including SWOTs, KPIs and latest activity) and competitive landscape tables.
BMI Industry View
An at-a-glance perspective on the latest regulatory developments, key forecast indicators and major corporate developments, covering the prescription, OTC and generics markets. The pharmaceuticals and healthcare SWOT outlines strategic factors that affect the basic assumptions underpinning BMIs forecast analysis, and taken together with BMIs political, economic and business environment SWOTs, it gives a complete overview of market climate.
BMI Industry Forecast Scenario
Industry forecasts to end-2019 for all key indicators, supported by explicit assumptions, plus analysis of key downside risks to the main forecasts:
BMIs Pharmaceuticals and Healthcare Risk Reward Index
- Healthcare: Total healthcare expenditure (USDbn), healthcare expenditure (% of GDP), healthcare expenditure per capita (USD), hospital beds, doctors, and birth & mortality rates (all per 000 population).
- Pharmaceutical Market: Drug expenditure in USDbn, % of GDP and per capita (USD).
- Patented Drug Market: Prescription drug sales (USDbn & % of total sales).
- Generic Drug Market: Generic product sales (USDbn), generic sales (% of total sales).
- OTC Drug Market: OTC sales (USDbn & % of total sales).
- Macroeconomic Forecasts: Nominal and real GDP, % real GDP growth, % private consumption growth, % industrial output growth, % consumer price index, % GDP price deflator, exports, imports, trade balance, current account balance, foreign direct investment, exchange rate against USD, government expenditure and external debt.
BMIs Risk Reward Index provides investors (both national and multinational) looking for opportunities in the region with a clear country-comparative assessment of the markets risks and potential rewards. Each of the country markets are scored using a sophisticated model that includes more than 40 industry, economic and demographic data points to provide indices of highest to lowest appeal to investors, with each position explained.
A snapshot of key market characteristics, including total size of the pharmaceuticals and healthcare segments, growth drivers, leading therapeutic areas and the competitive landscape
A focus on government healthcare reforms, epidemiological trends, mergers and acquisitions, product launches, market entries, FDI activity, R&D, biotechnology, clinical trials and supply chain issues.
Details of the industry regulatory framework and key legislation covering the licensing of new products/services, pricing and reimbursements, intellectual property, taxation and advertising, as well as analysis of the overall regulatory burden.
The competitive landscape section provides comparative company analyses and index by USD sales and % share of total sales for the total pharmaceutical sector, as well as the OTC, generics and distribution sub-sectors.
Examines the competitive positioning and short- to medium-term business strategies of key industry players. Strategy is examined within the context of BMIs industry forecasts, our macroeconomic views and our understanding of the wider competitive landscape to generate Company SWOT analyses. The latest financial and operating statistics and key company developments are also incorporated within the company profiles, enabling a full evaluation of recent company performance and future growth prospects.
*Company profiles are not available for every country. Those reports instead contain information on the current activities of prominent companies operating in the market.
Lebanon's healthcare system is under enormous strain as the number of Syrian refugees seeking treatment in the country has sharply risen. Continued political instability will negatively impact government policy regarding healthcare and will in turn put the pharmaceutical sector at risk. However, high per capita spending, an increasing burden of non-communicable diseases along with efforts by the Health Ministry to tackle high levels of corruption within the sector will help sustain market growth in the coming years.
BMI Industry View
Pharmaeutical Market Forecast
Table: Pharmaceutical Sales, Historical Data And Forecasts (Lebanon 2010-2018)
Healthcare Market Forecast
Table: Healthcare Expenditure Trends, Historical Data And Forecasts (Lebanon 2010-2018)
Table: Government Healthcare Expenditure Trends, Historical Data And Forecasts (Lebanon 2010-2018)
Table: Private Healthcare Expenditure Trends, Historical Data And Forecasts (Lebanon 2010-2018)
Prescription Drug Market Forecast
Table: Prescription Drug Market Indicators, Historical Data And Forecasts (Lebanon 2010-2018)
Patented Drug Market Forecast
Table: Patented Drug Market Indicators, Historical Data And Forecasts (Lebanon 2010-2018)
Generic Drug Market Forecast
Table: Generics Drug Market Indicators, Historical Data And Forecasts (Lebanon 2010-2018)
OTC Medicine Market Forecast
Table: Over-The-Counter (OTC) Medicine Market Indicators, Historical Data And Forecasts (Lebanon 2010-2018)
Pharmaceutical Trade Forecast
Table: Pharmaceutical Trade Data And Forecasts (Lebanon 2012-2018)
Table: Pharmaceutical Trade Data And Forecasts local currency (Lebanon 2012-2018)
Other Healthcare Data
Key Risks To BMI's Forecast Scenario
Table: Lebanon - Economic Activity
Industry Risk Reward Ratings
Middle East & Africa Risk/Reward Ratings
Lebanon Risk/Reward Ratings
Industry Trends And Developments
Regional Healthcare Collaboration
Public Sector Procurement
Intellectual Property Regime
Free Trade Agreements
Pharmaceutical Sector Developments
Retail Pharmacy Sector
Benta Pharnaceutical Industries (BPI)
Chalhoub Pharmaceuticals (CHAPHA)
Merck & Co
Johnson & Johnson (J&J)
Table: Lebanon's Population By Age Group, 1990-2020 ('000)
Table: Lebanon's Population By Age Group, 1990-2020 (% of total)
Table: Lebanon's Key Population Ratios, 1990-2020
Table: Lebanon's Rural And Urban Population, 1990-2020
Pharmaceutical Expenditure Forecast Model
Healthcare Expenditure Forecast Model
Notes On Methodology
Risk/Reward Ratings Methodology
Table: Pharmaceutical Risk/Reward Ratings Indicators
This report does not have a list of Companies Mentioned available
This report does not have a press release associated with it